Ποια είναι η τιμή για TetraLogic Pharmaceuticals Corporation (TLOG)

Η τιμή για TetraLogic Pharmaceuticals Corporation (TLOG) είναι $0.00004

Ποια είναι η κεφαλαιοποίηση αγοράς για TetraLogic Pharmaceuticals Corporation (TLOG)

Η κεφαλαιοποίηση αγοράς για TetraLogic Pharmaceuticals Corporation (TLOG) είναι $979.00

TetraLogic Pharmaceuticals Corporation (TLOG) Τιμή και Κεφαλαιοποίηση Αγοράς

TetraLogic Pharmaceuticals Corporation operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on identifying and advancing small-molecule treatments for cancer and infectious diseases. The company's development pipeline features two key clinical-stage drug candidates: birinapant and SHAPE. Birinapant, a small molecule, functions as a Second Mitochondrial Activator of Caspases (SMAC) mimetic, promoting programmed cell death, or apoptosis, in compromised cells. SHAPE, another proprietary compound, is a histone deacetylase (HDAC) inhibitor intended for topical administration to address early-stage cutaneous T-cell lymphoma. Furthermore, TetraLogic Pharmaceuticals has a research collaboration with the Walter and Eliza Hall Institute of Medical Research to explore the application of SMAC-mimetics, including birinapant, in treating infectious diseases. Founded in 2001 as Gentara Corporation, the company adopted its current name, TetraLogic Pharmaceuticals Corporation, in January 2006 and maintains its headquarters in Malvern, Pennsylvania.

Η τιμή για TLOG	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$221,701 $979.00	NVDA	$5.426T	+554,252,703,444.54%
$180,839 $979.00	AAPL	$4.426T	+452,097,539,372.83%
$169,918 $979.00	GOOG	$4.159T	+424,793,791,745.61%
$149,646 $979.00	MSFT	$3.663T	+374,114,242,151.86%
$118,157 $979.00	AMZN	$2.892T	+295,391,726,635.21%

Η τιμή για TLOG

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$221,701 $979.00